Unsymmetrical bisquinolines with high potency against P. falciparum Malaria

Article abstract of DOI:10.3390/molecules25092251

Quinoline-based scaffolds have been the mainstay of antimalarial drugs, including many artemisinin combination therapies (ACTs), over the history ofmoderndrugdevelopment. Althoughmuch progress has beenmade in the search for novel antimalarial scaffolds, itmay be that quinolineswill remain useful, especially if very potent compounds fromthis class are discovered. We report here the results of a structure-activity relationship(SAR) study assessingpotentialunsymmetrical bisquinoline antiplasmodial drug candidates using in vitro activity against intact parasites in cell culture. Many unsymmetrical bisquinolineswere found to be highly potent against both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum parasites. Further work to develop such compounds could focus on minimizing toxicities in order to find suitable candidates for clinical evaluation.

Full text of DOI:10.3390/molecules25092251

molecules
Article
Unsymmetrical Bisquinolines with High Potency
against P. falciparum Malaria
Katherine M. Liebman 1,2, Steven J. Burgess 1, Bornface Gunsaru 2, Jane X. Kelly 2,3, Yuexin Li 3,
Westin Morrill 1, Michael C. Liebman 2 and David H. Peyton 1,2,
*
1
DesignMedix, Inc., Portland, OR 97201, USA; kliebman@pdx.edu (K.M.L.); sburgess@nogeire.com (S.J.B.);
westin.morrill@gmail.com (W.M.)
Department of Chemistry, Portland State University, Portland, OR 97207, USA; bgunsaru@yahoo.com (B.G.);
kellyja@ohsu.edu (J.X.K.); michael.liebman343@gmail.com (M.C.L.)
Portland VA Research Foundation, Portland, OR 97239, USA; liyu@ohsu.edu
Correspondence: peytond@pdx.edu; Tel.: +1-503-805-1291
2
3
*
ꢀꢁꢂꢀꢃꢄꢅꢆꢇ
Academic Editor: Harinantenaina Liva Rakotondraibe
Received: 20 April 2020; Accepted: 7 May 2020; Published: 10 May 2020
ꢀꢁꢂꢃꢄꢅꢆ
Abstract: Quinoline-based scaffolds have been the mainstay of antimalarial drugs, including many
artemisinincombinationtherapies(ACTs), overthehistoryofmoderndrugdevelopment. Althoughmuch
progress has been made in the search for novel antimalarial scaffolds, it may be that quinolines will remain
useful, especially if very potent compounds from this class are discovered. We report here the results of a
structure-activityrelationship(SAR)studyassessingpotentialunsymmetricalbisquinolineantiplasmodial
drug candidates using in vitro activity against intact parasites in cell culture. Many unsymmetrical
bisquinolines were found to be highly potent against both chloroquine-sensitive and chloroquine-resistant
Plasmodium falciparum parasites. Further work to develop such compounds could focus on minimizing
toxicities in order to find suitable candidates for clinical evaluation.
Keywords: malaria; P. falciparum; drug discovery; SAR; structure–activity relationship; drug resistance
1. Introduction
Malaria remains a challenge for worldwide public health. The World Health Organization estimated
the total number of deaths in 2018 to be 405,000, down from 585,000 in 2010 and 864,000 in 2000 [1,2]
While there has been considerable progress and optimism about malaria elimination, eradication
may not be rapid. So as not to squander the progress that has been made, every possible new tool is
needed, especially in light of the development of drug resistance to nearly every current therapeutic
for P. falciparum malaria [3–5].
.
Bisquinolines have been explored for malaria for a long time, and the most successful of these,
piperaquine (PPQ; Table 1), has been used as both mono- and combination therapy [
is a long-acting component of dihydroartemisinin-piperaquine, one of the artemisinin combination
therapies recommended by the World Health Organization to treat P. falciparum malaria [ ]. PPQ and
a variety of analogs were first synthesized in France at Rh ne-Poulenc [ 11] (Table 1) and further
developed in China. Clinical trials performed in China during the early 1970s led to piperaquine’s
wide use in China, both as treatment and as prophylaxis for P. falciparum and P. vivax malaria [12 16].
6]. Piperaquine
7
ô
8–
–
Piperaquine is believed to work by a mechanism similar to that of chloroquine and other 4-
aminoquinolines [15]; however, it retains activity against many chloroquine-resistant (CQR) strains,
perhapsbecauseitslargesizepreventsitbeingexportedbythechloroquineresistancetransporter[15,17–20]
.
However, following its introduction in China, resistance to PPQ monotherapy became common in the areas
in which it was heavily used [12–14]. Unfortunately, resistance to the combination dihydroartemisinin–
Molecules 2020, 25, 2251; doi:10.3390/molecules25092251
www.mdpi.com/journal/molecules

Molecules 2020, 25, 2251
2 of 15
piperaquine has now arisen and continues to increase in southeast Asia [21–23]. Recent work is uncovering
the mechanisms of piperaquine resistance [5,24–29].
In addition to PPQ itself, a wide range of other bis-4-aminoquinoline compounds have been shown
to have antiplasmodial activity, tending to be active against both chloroquine-sensitive (CQS) and CQR
strains [17
to the discovery of Ro 48–6910, which was evaluated in preclinical studies but was regrettably found to
be phototoxic [19 37 41 44]. More recently, Kondaparla et al. have explored a series of unsymmetrical
,19,30–40]. During the 1990s, a study of bis-quinolines by Vennerstrom and co-workers led
,
,
–
bisquinolines linked by an amide and an adjacent chiral center [17].
Here, we report on a series of simple but unsymmetrical bisquinolines based on the 4-aminoquinoline
structure derived from CQ and other antimalarial drugs. One of these has unusually potent in vitro
activity against CQS and CQR malaria, indicating that structures in this series may be worth further
evaluation as antimalarials.
2. Results
In vitro antiplasmodial activities against P. falciparum are given in Table 1. The bisquinoline compounds
vary in their alkylamine linkage between quinoline ring systems (alkyl, piperazine, or piperidine moieties).
Compound
1
is similar to PPQ, except that it lacks the quinoline Cl atoms. Like piperaquine, the bisquinoline
was originally reported by Rh ne-Poulenc during the 1960s [45]; it is here compared with a des-chloro
. Finally, we report a series of compounds based on the unsymmetrical bisquinoline compound
5
ô
analog,
7
6
that vary in their quinoline ring substitution pattern (7-chloro, 8-trifluoromethyl, or no substituent).
For comparison to the bisquinolines, we also include compounds 2 and 4 from earlier work in our laboratory,
together with 3, the des-chloro analog of compound 2.
As can be seen from these results, bisquinoline structures can give very potent antimalarial
activities against the standard laboratory-adapted D6, Dd2, and 7G8 strains, the last two being accepted
CQR strains. However, cytotoxicity of an unsymmetrical bisquinoline assessed in mouse spleen
lymphocytes was found to be elevated relative to that of chloroquine.
Table 1. In vitro antiplasmodial activities of bisquinoline and related compounds.
Activity (IC50; nM)
Cytotoxicity
Compound
Structure
(LC50; nM) Mouse
Spleen Lymphocytes
D6
Dd2
7G8
CQ
6.9
102
106
12,400
PPQ
0.7
1.3
1.5
4.1
1
7.4
1.5
2 [46]
2.4
1.5
3.7
5.0
1100
1600
3

Molecules 2020, 25, 2251
3 of 15
Table 1. Cont.
Cytotoxicity
Activity (IC50; nM)
Compound
4 (DM1157) [46,47]
5 [45]
Structure
(LC50; nM) Mouse
Spleen Lymphocytes
D6
Dd2
7G8
0.2
0.4
2.2
1.8
0.1
6500
0.7
6
7
8
9
0.15
4.9
0.36
9.8
0.33
25
190
0.68
0.68
2.1
0.63
0.41
2.1
10
15
89
106
11
12
13
3.0
4.5
33
<2.5
<2.5
56
<2.5
<2.5
100
3. Discussion
The in vitro antiplasmodial activities obtained for the bisquinolines reported here are given in
Table 1, together with chloroquine, piperaquine, and three compounds from earlier work in our laboratory
that contain a chloroquine moiety with an attached reversal agent (“reversed chloroquines”) [46
,48].
Some of the compounds, particularly compound , were found to be very active in vitro. Potency of these
6
bisquinolines may be enhanced by the potential of both of the quinoline moieties in these molecules to
interact with heme (a commonly invoked mechanism of action of the 4-aminoquinolines), an advantage
that would also be available to piperaquine. However, a difference between compound
is that the 4-aminoquinoline nitrogens of compound are secondary, while those of PPQ are tertiary;
much of the earlier work on 4-aminoquinolines and 9-aminoacridines has focused on secondary 4-amino
derivatives [49 53]. During the 1930s and 1940s, prior to research indicating that the site of action
6 and piperaquine
6
–
of 4-aminoquinolines and 9-aminoacridines is the parasite’s acidic digestive vacuole, Schönhofer and
coworkers observed that alkylation of the 9-amino group of quinacrine (Atebrine) diminished antimalarial
activity. To explain this, they proposed that antimalarial activity of quinacrine-like compounds required

Molecules 2020, 25, 2251
4 of 15
an ability to tautomerize, with the 9-NH shifting to the ring N (this is not possible for the tertiary 9-amino
derivatives [49]). The in vitro antiplasmodial activity of chloroquine [15 50 54] as well as reversed
,
,
chloroquine compounds (unpublished work from our laboratory) is also reduced, but not eliminated,
by the presence of a tertiary 4-amino group. Egan has shown that aminoquinolines capable of stabilizing
a positive charge on the quinoline ring nitrogen (2- and 4-aminoquinolines) have strong heme binding
and are more basic, potentially leading to increased accumulation at the site of action in the parasite’s
digestive vacuole (Figure 1 [55]).
Figure 1. Resonance stabilization of the positive charge on the protonated ring nitrogen of chloroquine [55].
While tertiary 4-aminoquinolines could also be capable of such resonance stabilization, it has
been suggested that PPQ has steric hindrance between the proton in position 5 of the quinoline ring
system and the piperazine methylene groups that results in twisting of the substituted 4-amino group
out of the plane of the ring, reducing resonance stabilization of the alternative form. [15]. This would
then result in reduced basicity of the ring nitrogen for such tertiary compounds, leading to reduced
accumulation in the digestive vacuole. Experimental determination of the pKas of piperaquine has
shown that it is indeed less basic than CQ [15]. In spite of these observations, the bisquinoline
PPQ–with two tertiary 4-aminoquinolines–is a highly active antimalarial. Warhurst proposed that
while piperaquine’s accumulation in the aqueous acidic vacuole should be somewhat less than that
of chloroquine, its accumulation in the lipid portions of the vacuole is expected to be much greater
(based on the empirically determined pKas and cLogP of both compounds; [15]). This may be significant
in view of the evidence that hemozoin may form at the surface of or inside of lipid droplets within the
digestive vacuole [15,56–58].
Whatever the reasons behind PPQ’s strong activity, the fact that compound
6 has even higher
in vitro antiplasmodial potency over that of piperaquine may suggest that the presence of a tertiary
amine is indeed detrimental to 4-aminoquinoline antimalarials and that piperaquine’s activity represents
a compromise between the detriment of the tertiary 4-amino group and other more favorable properties.
Compound
6 may possess the positive features of PPQ with the additional advantage of the secondary
quinoline-4-amino group.
Bisquinoline compounds retain much of their activity against many CQR strains of P. falciparum
malaria. To explain piperaquine’s activity against CQR strains, it has been suggested that the increased
bulk and lipophilicity of PPQ relative to that of CQ causes the bisquinoline to be unable to be exported
through the P. falciparum chloroquine resistance transporter (PfCRT) [15]. We have already suggested
that reversed chloroquine molecules and PPQ can block export by PfCRT and so give high activity [59].
This may also apply to compound
6, which is structurally similar to the reversed chloroquine compound
4 (DM1157) [46,47].
For the potent unsymmetrical bisquinoline compound
6
and its analogs, both ring systems seem
to be of equal importance to the antiplasmodial activity. This conclusion is apparent from the various
analogs with 8-trifluoromethyl substitution, which has been observed to be an inactivating substitution
pattern for reversed chloroquine-type 4-aminoquinoline antiplasmodial candidates (unpublished
work in our lab) and for other 4-aminoquinolines, including bisquinolines, although not for quinoline
methanols, such as mefloquine [60–64] (and in one study, not for 4-aminobisquinolines where a 2-
trifluoromethyl substituent was already present [65]). Thus, compound 10, having the 8-CF3 substitution
at both quinoline rings without the 7-Cl, loses at least two orders of magnitude of potency relative to
compound 6. However, for analogues of 6 with a single 8-trifluoromethyl substitution (compounds 8

Molecules 2020, 25, 2251
5 of 15
and
9), activity was almost as high as the parent
6. These results suggest that either quinoline ring system
is equally capable of participating in the antimalarial action of compound 6.
Others have noted that the activity of CQ and its analogs is detrimentally affected by removal of
the 7-chloro substituent [55
chloroquine compounds (see compounds
activity is minimally affected by removal of chlorine. For two other bisquinoline scaffolds,
and , we found that activity of des-chloro analogs was reduced compared to the 7-chloro parent
(compare to 11 12, and 13 and to ), although not as much as has been observed for chloroquine
and analogs. Both and differ from piperaquine in having a secondary rather than tertiary 4-amino
group. This result suggests that secondary amino bisquinolines are more sensitive to removal of
chlorine than piperaquine. Even when just one ring system of lacks a 7-chloro substituent, activity is
slightly diminished relative to the parent . For the 8-CF3 series, it appears that even with one ring
,
66
–
73], but we have observed that this may not be the case for reversed
and , Table 1; [48]). Here, we report that PPQ’s in vitro
45
2
3
5
[ ]
6
6
,
5
7
5
6
6
6
system “inactivated”, antimalarial activity does not decrease significantly. This does not appear to be
the case for des-chloro substitution.
4. Materials and Methods
Reagents and solvents were purchased from TCI America, Aldrich Chemical, Alfa Aesar, or Acros
Organics and were used as received without further purification.
4.1. General Synthetic Methods
Except for 4,7-dichloroquinoline, substituted 4-chloroquinolines were made by the Gould–Jacobs
reaction, followed by chlorination with phosphorus oxychloride (Figure 2 [74–77]):
Figure 2. Synthesis of 4-chloroquinolines by the Gould–Jacobs reaction, followed by chlorination with
phosphorus oxychloride.
Compound
(Figure 3):
1
was made by reaction of 4-(piperazin-1-yl)quinoline [78,79] with 1,3-dibromopropane
Figure 3. Synthesis of compound 1.
Compound
5 [45] and 7 were made by the reaction of the appropriate 4-chloroquinoline with
1,4-bis(3-aminopropyl)piperazine in phenol (Figure 4 [51,80]):

Molecules 2020, 25, 2251
6 of 15
Figure 4. Synthesis of compounds 5 and 7.
The synthesis of the unsymmetrical bisquinoline compounds required the synthesis of two
different 4-aminoquinoline starting materials: a 3-(quinolin-4-ylamino)propyl methanesulfonate and
an N-(piperidin-4-yl)quinolin-4-amine.
To make the 3-(quinolin-4-ylamino)propyl methanesulfonates, the appropriate 4-chloroquinoline
was allowed to undergo solvolysis with 3-amino-1-propanol to give a 4-amino alcohol, and the hydroxyl
group was then converted to a methanesulfonyl group (Figure 5 [46,59]):
Figure 5. Reaction of 4-chloroquinolines with 3-amino-1-propanol, followed by activation of the resulting
alcohol by methanesulfonyl chloride.
TheN-(piperidin-4-yl)quinolin-4-aminesweresynthesizedbyreactionoftheappropriate4-chloroquinoline
with 1-carbethoxy-4-aminopiperidine in phenol [51,80], followed by removal of the carbethoxy group
by heating with aqueous caustic soda in ethanol (Figure 6 [81]):
Figure 6. Synthesis of one starting material for unsymmetrical bisquinoline compounds.
Reactionofthetwoquinolinestartingmaterialsthenprovidedthedesiredbisquinolines(Figure7[46,82]):
Figure 7. Synthesis of unsymmetrical bisquinoline compounds.
Bisquinoline products were purified by recrystallization and sometimes column chromatography.
A different, less satisfactory synthetic method was initially used to obtain compound 6. This is detailed
in the Supplementary Materials.

Molecules 2020, 25, 2251
7 of 15
4.2. Characterization of Products
Bisquinoline final products were characterized by NMR (1H, 13C, COSY, HSQC, NOESY, and 19
F
if applicable), HPLC, and HR-MS (details of methods used below). Intermediates were characterized
by 1H NMR and in some cases HPLC and HR-MS.
1H, 13C, COSY, HSQC, HMBC, and 19F NMR experiments were run on a Bruker 400 MHz or
600 MHz spectrometer. (Note: Trifluoromethyl carbons were not observed in 13C NMR spectra, likely
due to reduction in intensity due to 19F–13C splitting as well as the lack of the 1-bond 1H–13C nuclear
Overhauser effect (NOE).) HPLC was performed using UV detection at 254 and 325 nm using a Varian
ProStar 325 UV/vis dual wavelength detector. Three HPLC methods were used. For HPLC method A,
a SUPELCO Ascentis RP-Amide 5
of 95:5 to 30:70 water with 0.1% formic acid (v/v)/acetonitrile. For HPLC method B, a SUPELCO
Ascentis C18 5 m, 4.6 150 mm column was used, eluting with 95% water and 5% acetonitrile.
For HPLC method C, a SUPELCO Ascentis C18 5 m, 4.6 150 mm column was used, eluting with
µm, 4.6 mm
×
150 mm column was used, eluting with a gradient
µ
×
µ
×
a gradient from 95:5 to 5:95 water with 0.1% formic acid (v/v)/acetonitrile. High resolution mass
spectrometry was performed on a Bruker micrOTOF-Q instrument. Results were obtained using
electrospray ionization (ESI) in the positive mode at a flow rate of 0.4 mL/min with 1:1 methanol–water.
Gas chromatography–mass spectrometry (GC–MS) was performed using a Hewlett Packard HP5890
Series II gas chromatograph with a 30-m DB5 column. The oven temperature was set at 130 ◦C for
2 min and then increased to 300 ◦C at the rate of 30 ◦C per minute. This instrument was used with the
kind permission of Dr. Michael Riscoe of the Portland Veterans Affairs Medical Center.
Example Synthesis: Compound 6
(Further synthetic methods are provided in the Supplementary Materials).
3-(7-Dichloroquinolin-4-ylamino)propanol (Figure 8 [59,82]):
Figure 8. Structure of 3-(7-Dichloroquinolin-4-ylamino)propanol.
The title compound was synthesized without deviating from methods previously described [59
(a pale tan solid, mp = 148.5–151.0 ◦C).
,82]
3-(7-Chloroquinolin-4-ylamino)propyl methanesulfonate (Figure 9 [59,82]):
Figure 9. Structure of 3-(7-Chloroquinolin-4-ylamino)propyl methanesulfonate.
3-(7-Dichloroquinolin-4-ylamino)propanol (1.88 g◦, 7.9 mmol), triethylamine (1.66 mL, 1.2 mmol),
and anhydrous THF (100 mL) were cooled below 0 C on ice/salt, and methanesulfonyl chloride
(0.71 mL, 9.1 mmol) was added dropwise. After stirring for an hour on ice, TLC indicated that reaction
was not complete, and therefore additional triethylamine (0.83 mL, 6.0 mmol) and methanesulfonyl
chloride (0.36 mL, 6.0 mmol) were added. After a further hour, TLC indicated that no quinoline starting
material remained. The reaction mixture was diluted with ethyl acetate (30 mL) and shaken with
saturated sodium bicarbonate (30 mL), followed by extraction of the aqueous layer with additional
ethyl acetate (3
×
10 mL). The pooled ethyl acetate layers were washed with brine (10 mL), dried over

Molecules 2020, 25, 2251
8 of 15
magnesium sulfate, and evaporated under reduced pressure with warming to obtain a pale yellow,
fluffy solid (1.86 g, 81%).
1H NMR
δ (ppm)(CDCl3): 8.53 (1 H, d, J = 5.37 Hz, ClQ-C2-H), 7.95 (1 H, d, J = 2.18 Hz, ClQ-C8-H),
7.72 (1 H, d, J = 8.97 Hz, ClQ-C5-H), 7.38 (1 H, dd, J = 8.94, 2.18 Hz, ClQ-C6-H), 6.42 (1 H, d, J = 5.40 Hz,
ClQ-C3-H), 5.55 (1 H, br t, J = 5.75 Hz, NH), 4.42 (2 H, t, J = 5.66 Hz, CH2O), 3.58 (2 H, td, J = 6.34,
5.77 Hz, CH2N), 3.06 (3 H, s, CH3), 2.18 (2 H, m, CH2).
Ethyl 4-((7-chloroquinolin-4-yl)amino)piperidine-1-carboxylate (Figure 10 [51,80])
Figure 10. Structure of Ethyl 4-((7-chloroquinolin-4-yl)amino)piperidine-1-carboxylate.
4,7-Dichloroquinoline (2.00 g, 10 mmol), ethyl 4-amino-1-piperidine carboxylate (1.83 g, 11 mmol),
and phenol (5.70 g, 61 mol) were heated at 90 ◦C in a sealed Carius vessel for 48 h. TLC indicated
that unreacted 4,7-dichloroquinoline remained, and therefore additional ethyl 4-amino-1-piperidine
carboxylate (0.39 g, 2.3 mmol) was added. The vessel was again sealed and heated for a further 7 days,
whereupon TLC indicated that no unreacted quinoline remained. The reaction mixture was diluted
with chloroform (50 mL) and rinsed with 10% caustic soda (6
×
10 mL), followed by further rinsing
with brine (3 10 mL). The organic layer was dried over MgSO4 and concentrated under reduced
×
pressure with warming to yield a thick, tan liquid containing some solid material. After standing 14 h,
this was taken up in boiling solvent (50/50 ethyl acetate/95% ethanol (v/v)) and allowed to cool and
concentrate at room temperature. The crystals thus formed were recovered from the remaining 5 mL
of solvent by vacuum filtration (off-white crystals, 1.18 g, 35%, mp = 197.3–198.8 ◦C).
1H NMR
δ (ppm)(CDCl3): 8.54 (1 H, d, J = 5.36 Hz), 7.96 (1 H, d, J = 2.17 Hz), 7.66 (1 H, d, J = 8.98 Hz),
7.37 (1 H, dd, J = 8.94, 2.19 Hz), 6.46 (1 H, d, J = 5.41 Hz), 4.92 (1 H, br d, J = 7.25 Hz), 4.16 (4 H, br s
overlaps q, J = 7.13 Hz), 3.68–3.69 (1 H, m), 3.04 (2 H, td, J = 12.56, 2.82 Hz), 2.11–2.20 (2 H, m), 1.51–1.53
(2 H, m), 1.28 (3 H, t, J = 7.11 Hz).
MS (ESI): m/z 334.13271 M + H (calculated 334.13168).
HPLC (method A) tR = 10.55 min (99% pure).
7-Chloro-N-(piperidin-4-yl)quinolin-4-amine (Figure 11 [81])
Figure 11. Structure of 7-Chloro-N-(piperidin-4-yl)quinolin-4-amine.
Ethyl 4-((7-chloroquinolin-4-yl)amino)piperidine-1-carboxylate (2.45 g, 7.3 mmol), 95% ethanol
(100 mL), and 10% caustic soda (4.5 mL) were allowed to heat, stirring, at reflux for 4 days. As TLC
indicated that the reaction was not complete, 0.5 mL of 50% caustic soda was added, and reflux was
continued for a further 3 days. TLC then indicated that the reaction was complete. The reaction

Molecules 2020, 25, 2251
9 of 15
solvent was removed under reduced pressure with warming, and the residue was partitioned between
chloroform (20 mL) and water (50 mL). After separation, the aqueous layer was extracted with
additional chloroform (3
×
10 mL), and the pooled organic layers were dried (MgSO4) and concentrated
under reduced pressure with warming to yield a tan solid (1.05 g). A cream-colored solid was also
isolated from the aqueous layer by vacuum filtration (1.04 g). NMR indicated that both solids obtained
were the desired product (total yield 1.83 g, 96%, mp = 166.3–169.4 ◦C).
1H NMR
δ (ppm)(CDCl3): 8.52 (1 H, d, J = 5.39 Hz), 7.96 (1 H, d, J = 2.18 Hz), 7.65 (1 H, d, J = 8.96 Hz),
7.37 (1 H, dd, J = 8.93, 2.19 Hz), 6.45 (1 H, d, J = 5.42 Hz), 4.87 (1 H, br d, J = 7.35 Hz), 3.61–3.62 (1 H,
m), 3.19 (2 H, dt, J = 12.68, 3.70 Hz), 2.79–2.81 (2 H, m), 2.15–2.19 (2 H, m), 1.50–1.50 (2 H, m).
MS (ESI): m/z 262.11116 M + H (calculated 262.11065).
HPLC (method A) tR = 2.74 min (94% pure).
Compound
6 (7-Chloro-N-(3-(4-((7-chloroquinolin-4-yl)amino)piperidin-1-yl)propyl)quinolin-4-amine)
(Figure 12 [46,82])
Figure 12. Synthesis of Compound 6.
3-(7-Chloroquinolin-4-ylamino)propyl methanesulfonate (1.20 g, 3.8 mmol), 7-chloro-N-(piperidin-
4-yl)quinolin-4-amine (1.05 g, 4.0 mmol), potassium carbonate (5.7 mmol, 0.79 g), a catalytic amount of
potassium iodide, and 50 mL anhydrous acetonitrile were allowed to heat for 48 h at reflux, whereupon
TLC indicated that the reaction was complete. The reaction mixture was diluted with water (50 mL) and
vacuum filtered. The filtrate was concentrated under reduced pressure with warming, and the reaction
mixture was partitioned between 50/50 dichloromethane/chloroform (20 mL) and 10 mL saturated
sodium bicarbonate, followed by further extraction with three 10 mL portions of dichloromethane.
The pooled organic layers were dried over anhydrous magnesium sulfate and concentrated under
reduced pressure. The resulting solid was combined with the material filtered from the reaction
mixture and recrystallized from 95% ethanol, which afforded the desired product as a pale yellow,
crystalline solid (1.30 g). Concentration of the mother liquor yielded a further crop of crystals (0.06 g,
total yield 71%, mp = 224–227 ◦C (dec)).
1H NMR
δ (ppm)(CDCl3): 8.56 (1 H, d, J = 5.33 Hz, Q1-C2-H), 8.53 (1 H, d, J = 5.33 Hz, Q2-C2-H), 7.99
(1 H, d, J = 2.16 Hz, Q1-C5-H), 7.97 (1 H, d, J = 2.14 Hz, Q2-C5-H), 7.78 (1 H, d, J = 8.90 Hz, Q2-C8-H),
7.71 (1 H, d, J = 8.95 Hz, Q1-C8-H), 7.43 (1 H, dd, J = 8.89, 2.18 Hz, Q1-C6-H), 7.35 (1 H, dd, J = 8.87,
2.16 Hz, Q2-C6-H), 7.02 (1 H, br t, J = 4.27 Hz, Q1-C4-N
d, J = 5.37 Hz, Q2-C3-H), 4.92 (1 H, br d, J = 6.78 Hz, Q2-N
= 6.01, JNH = 4.35 Hz, Q1-NHCH2CH2CH2), 3.06 (2 H, m, piperidine-CH
2.67 (2 H, t, JCH2 = 5.64 Hz, Q1-NHCH2CH2CH2), 2.33 (2 H, m, piperidine-CH
chain), 2.28 (2 H, m, piperidine CH 2 adjacent to CH-NH-Q2), 1.99 (2 H, m, Q1-NHCH2CH2CH2),
1.75 (water signal overlaps m, ~2 H, piperidine CH × 2 adjacent to CH-NH-Q2).
H
), 6.47 (1 H, d, J = 5.37 Hz, Q1-C3-H), 6.38 (1 H,
), 3.65 (1 H, m, Pip-C ), 3.42 (2 H, td, JCH2
2 adjacent to alkyl chain),
2 adjacent to alkyl
H
H
×
×
×
13C NMR
(ppm)(CDCl3): 152.3 (Q1-C2), 152.0 (Q2-C2), 150.4, 149.4, 149.3, 148.4, 135.1, 134.7, 129.1
(Q-C5), 129.0 (Q-C5), 125.6 (Q1-C6), 124.8 (Q2-C6), 121.7 (Q2-C8), 120.7 (Q1-C8), 117.5, 117.2, 99.6
(Q1-C3), 98.8 (Q2-C3), 58.2 (Q1-NHCH2CH2 H2), 52.5 (piperidine-C adjacent to alkyl chain), 49.5
(piperidine- H-NH-Q2), 43.9 (Q1-NH H2CH2CH2), 32.0 (piperidine-C adjacent to CH-NH-Q2), 24.4
(Q1-NHCH2CH2CH2).
δ
C
C
C

Molecules 2020, 25, 2251
10 of 15
Note: Q1 and Q2 denote the quinoline ring system on the left and that on the right of the structure,
respectively, as shown above. Spectra are provided in Supplementary Materials (Example spectra:
Compound 6).
MS (ESI): m/z 480.17456 M + H (calculated 480.17163).
HPLC (method A) tR = 6.93 min (97% pure).
4.3. In Vitro Studies on Inhibition of P. falciparum Parasite Growth
The antiplasmodial activities of the compounds in this study were determined by methods described
previously [46,83]. The following three strains of P. falciparum were used: (1) a chloroquine- sensitive
strain, D6; (2) a chloroquine-resistant strain, Dd2, originally isolated from southeast Asia; and (3) a
second chloroquine-resistant strain, 7G8, originally isolated from Brazil. The parasites were maintained
continuously in culture, and asynchronous cultures were used for testing. Samples of the cultures
were diluted to 0.2% parasitemia and 0.2% hemocrit using uninfected red blood cells and complete
cell growth medium (RPMI-1640 with 0.5% Albumax II). Chloroquine was used as a positive control.
Solutions of chloroquine and the test compounds were made at 10 mM in DMSO. These solutions were
diluted into complete cell growth medium. In a 96-well microplate, the stock solutions were diluted
with complete cell growth medium to provide triplicate wells at concentrations between 0 and 10−4
M, each having a final volume of 100 µL. A given assay was performed using concentrations either
in the range of 0.025 to 250 nM or 2.5 to 2500 nM. The plates were then incubated under standard
culture conditions for 72 h before harvesting. The SYBR Green-I fluorescence-based method [83] was
used to read the plates using a 96-well plate fluorescence reader (Gemini-EM, Molecular Devices) with
excitation and emission wavelengths of 497 and 520 nm, respectively. Fluorescence was plotted against
the logarithm of drug concentration. IC50 values were then obtained by curve fitting by nonlinear
regression analysis using Prism (Graph Pad) software. The IC50 obtained for the chloroquine-positive
control was then used to “normalize” the IC50 values obtained for the test compounds to the chloroquine
IC50 values of 6.9 nMD6, 102 nMDd2, and 108 nM7G8 [46].
5. Conclusions
The high in vitro antiplasmodial activity of compound
6 and its synthetic accessibility makes this
a compound of interest for further development as a potential antimalarial drug, particularly if it were
found to be active against piperaquine-resistant strains of Plasmodium, which is the case (D. Fidock,
private communication). However, for bisquinolines as well as for other classes of compounds, high
in vitro activity does not necessarily predict high activity in vivo. Additionally, the substantially
elevated cytotoxicity of
6 relative to CQ are cause for possible concern. It may be possible to improve
this feature by the design of further analogs within this series.
Supplementary Materials: The following are available online, Synthetic details for all compounds not described
in the main manuscript; Figure C1–C12: Detailed 1H & 13C NMR spectra for Compound 6.
Author Contributions: Conceptualization, D.H.P., S.J.B., and K.M.L.; methodology, J.X.K.; validation, J.X.K. and
Y.L.; investigation, K.M.L., B.G., Y.L., W.M., and M.C.L.; data curation, J.X.K.; writing—original draft preparation,
D.H.P.; writing—review and editing, K.M.L.; supervision, D.H.P.; funding acquisition, D.H.P. All authors have
read and agreed to the published version of the manuscript.
Funding: We thank the National Institutes of Health for grants (AI067837, AI072923, AI094959, and AI114806)
to D.H.P.
Acknowledgments: Much of the research described here was performed as part of the doctoral work of K.M.L.,
S.J.B., and B.G., who would like to thank their dissertation committees for valuable discussions and feedback:
Jonathan J. Abramson, Albert S. Benight, Jason Podrabsky, Reuben H. Simoyi, Kenneth Stedman, Robert Strongin,
and Mark Woods of Portland State University and Michael Riscoe of the Portland VA Medical Center. We would
also like to thank Rolf Winter of the Portland VA Medical Center for synthetic advice and Michael Riscoe for
allowing K.M.L. the use of the GC/MS instrumentation.

Molecules 2020, 25, 2251
11 of 15
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to
publish the results.
References
1.
2.
3.
4.
5.
6.
7.
World Health Organization (WHO). World Malaria Report 2016; World Health Organization Press: Geneva,
Switzerland, 2016.
World Health Organization (WHO). World Malaria Report 2019; World Health Organization Press: Geneva,
Switzerland, 2019.
Menard, D.; Dondorp, A. Antimalarial Drug Resistance: A Threat to Malaria Elimination. Cold Spring Harb.
Perspect. Med. 2017, 7. [CrossRef]
Nsanzabana, C. Resistance to Artemisinin Combination Therapies (ACTs): Do Not Forget the Partner Drug!
Trop. Med. Infect. Dis. 2019, 4, 26. [CrossRef]
Ross, L.S.; Fidock, D.A. Elucidating Mechanisms of Drug-Resistant Plasmodium falciparum. Cell Host
Microbe 2019, 26, 35–47. [CrossRef]
Keating, G.M. Dihydroartemisinin/Piperaquine: A review of its use in the treatment of uncomplicated
Plasmodium falciparum malaria. Drugs 2012, 72, 937–961. [CrossRef]
World Health Organization. Guidelines for the Treatment of Malaria, 3rd ed.; World Health Organization:
Geneva, Switzerland, 2015.
8.
9.
Au, B. Nouveaux Dérivés de la Quinoléine et Leur Préparation. France Patent FR84902, 14 June 1962.
Benazet, F. Plasmodium berghei and prolonged-action antimalarials. Ann. Soc. Belges. Med. Trop. Parasitol.
Mycol. 1965, 45, 459–472.
10. Schneider, J.; Bouvry, M.; Le Quellec, J. Plasmodium berghei and chemotherapy. Ann. Soc. Belges. Med. Trop.
Parasitol. Mycol. 1965, 45, 435–449.
11. Brevent. Nouveaux Dérivés de la Quinoléine et Leur Préparation. Belgium Patent BE633453, 1963.
12. Chen, C. Development of antimalarial drugs and their application in China: A historical review. Infect. Dis.
Poverty 2014, 3, 9. [CrossRef] [PubMed]
13. Davis, T.M.; Hung, T.Y.; Sim, I.K.; Karunajeewa, H.A.; Ilett, K.F. Piperaquine: A resurgent antimalarial drug.
Drugs 2005, 65, 75–87. [CrossRef] [PubMed]
14. Schlitzer, M. Malaria chemotherapeutics part I: History of antimalarial drug development, currently used
therapeutics, and drugs in clinical development. Chem. Med. Chem. 2007, 2, 944–986. [CrossRef] [PubMed]
15. Warhurst, D.C.; Craig, J.C.; Adagu, I.S.; Guy, R.K.; Madrid, P.B.; Fivelman, Q.L. Activity of piperaquine and
other 4-aminoquinoline antiplasmodial drugs against chloroquine-sensitive and resistant blood-stages of
Plasmodium falciparum. Role of beta-haematin inhibition and drug concentration in vacuolar water- and
lipid-phases. Biochem. Pharmacol. 2007, 73, 1910–1926. [CrossRef]
16. Chen, L.; Qu, F.Y.; Zhou, Y.C. Field observations on the antimalarial piperaquine. Chin. Med. J. 1982, 95,
281–286. [PubMed]
17. Kondaparla, S.; Agarwal, P.; Srivastava, K.; Puri, S.K.; Katti, S.B. Design, synthesis and in vitro antiplasmodial
activity of some bisquinolines against chloroquine-resistant strain. Chem. Biol. Drug Des. 2017, 89, 901–906.
[CrossRef]
18. Naude, B.; Brzostowski, J.A.; Kimmel, A.R.; Wellems, T.E. Dictyostelium discoideum expresses a malaria
chloroquine resistance mechanism upon transfection with mutant, but not wild-type, Plasmodium falciparum
transporter PfCRT. J. Biol. Chem. 2005, 280, 25596–25603. [CrossRef] [PubMed]
19. Vennerstrom, J.L.; Ellis, W.Y.; Ager, A.L., Jr.; Andersen, S.L.; Gerena, L.; Milhous, W.K. Bisquinolines. 1. N,N-bis(7-
chloroquinolin-4-yl)alkanediamines with potential against chloroquine-resistant malaria. J. Med. Chem. 1992
,
35, 2129–2134. [CrossRef] [PubMed]
20. Basco, L.K.; Ringwald, P. In vitro activities of piperaquine and other 4-aminoquinolines against clinical
isolates of Plasmodium falciparum in Cameroon. Antimicrob. Agents Chemother. 2003, 47, 1391–1394. [CrossRef]
[PubMed]

Molecules 2020, 25, 2251
12 of 15
21. Bai, Y.; Zhang, J.; Geng, J.; Xu, S.; Deng, S.; Zeng, W.; Wang, Z.; Ngassa Mbenda, H.G.; Zhang, J.; Li, N.; et al.
Longitudinal surveillance of drug resistance in Plasmodium falciparum isolates from the China-Myanmar
border reveals persistent circulation of multidrug resistant parasites. Int. J. Parasitol. Drugs Drug Resist. 2018
,
8, 320–328. [CrossRef]
22. Lon, C.; Manning, J.E.; Vanachayangkul, P.; So, M.; Sea, D.; Se, Y.; Gosi, P.; Lanteri, C.; Chaorattanakawee, S.;
Sriwichai, S.; et al. Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for
uncomplicated malaria in military personnel in northern Cambodia: An open-label randomized trial. PLoS ONE
2014, 9, e93138. [CrossRef]
23. van der Pluijm, R.W.; Imwong, M.; Chau, N.H.; Hoa, N.T.; Thuy-Nhien, N.T.; Thanh, N.V.; Jittamala, P.;
Hanboonkunupakarn, B.; Chutasmit, K.; Saelow, C.; et al. Determinants of dihydroartemisinin-piperaquine
treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: A prospective
clinical, pharmacological, and genetic study. Lancet Infect. Dis. 2019, 19, 952–961. [CrossRef]
24. Cowell, A.N.; Winzeler, E.A. The genomic architecture of antimalarial drug resistance. Brief. Funct. Genom.
2019, 18, 314–328. [CrossRef]
25. Briolant, S.; Henry, M.; Oeuvray, C.; Amalvict, R.; Baret, E.; Didillon, E.; Rogier, C.; Pradines, B. Absence of
association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and
pfnhe genes in Plasmodium falciparum. Antimicrob. Agents Chemother. 2010, 54, 3537–3544. [CrossRef]
26. Eastman, R.T.; Dharia, N.V.; Winzeler, E.A.; Fidock, D.A. Piperaquine resistance is associated with a copy
number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob. Agents
Chemother. 2011, 55, 3908–3916. [CrossRef] [PubMed]
27. Hao, M.; Jia, D.; Li, Q.; He, Y.; Yuan, L.; Xu, S.; Chen, K.; Wu, J.; Shen, L.; Sun, L.; et al. In vitro sensitivities
of Plasmodium falciparum isolates from the China-Myanmar border to piperaquine and association with
polymorphisms in candidate genes. Antimicrob. Agents Chemother. 2013, 57, 1723–1729. [CrossRef] [PubMed]
28. Pascual, A.; Madamet, M.; Bertaux, L.; Amalvict, R.; Benoit, N.; Travers, D.; Cren, J.; Taudon, N.; Rogier, C.;
Parzy, D.; et al. In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum
chloroquine resistance transporter gene. Malar. J. 2013, 12, 431. [CrossRef] [PubMed]
29. Ross, L.S.; Dhingra, S.K.; Mok, S.; Yeo, T.; Wicht, K.J.; Kumpornsin, K.; Takala-Harrison, S.; Witkowski, B.;
Fairhurst, R.M.; Ariey, F.; et al. Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum
resistance to the first-line antimalarial piperaquine. Nat. Commun. 2018, 9, 3314. [CrossRef]
30. Akhigbe, J.; Luciano, M.; Zeller, M.; Bruckner, C. Mono- and Bisquinoline-Annulated Porphyrins from
Porphyrin beta,beta’-Dione Oximes. J. Org. Chem. 2015, 80, 499–511. [CrossRef]
31. Basco, L.K.; Andersen, S.L.; Milhous, W.K.; Le Bras, J.; Vennerstrom, J.L. In vitro activity of bisquinoline
WR268,668 against African clones and isolates of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 1994, 50,
200–205. [CrossRef]
32. Elslager, E.F. Progress in malaria chemotherapy. 1. Repository antimalarial drugs. Prog. Drug. Res. 1969, 13,
170–216. [CrossRef]
33. Raynes, K. Bisquinoline antimalarials: Their role in malaria chemotherapy. Int. J. Parasitol. 1999, 29, 367–379.
[CrossRef]
34. Raynes, K.; Foley, M.; Tilley, L.; Deady, L.W. Novel bisquinoline antimalarials. Synthesis, antimalarial activity,
and inhibition of haem polymerisation. Biochem. Pharmacol. 1996, 52, 551–559. [CrossRef]
35. Ridley, R.G.; Matile, H.; Jaquet, C.; Dorn, A.; Hofheinz, W.; Leupin, W.; Masciadri, R.; Theil, F.P.; Richter, W.F.;
Girometta, M.A.; et al. Antimalarial activity of the bisquinoline trans-N1,N2-bis (7-chloroquinolin-4-yl)
cyclohexane-1,2-diamine: Comparison of two stereoisomers and detailed evaluation of the S,S enantiomer,
Ro 47–7737. Antimicrob. Agents Chemother. 1997, 41, 677–686. [CrossRef]
36. van Heerden, L.; Cloete, T.T.; Breytenbach, J.W.; de Kock, C.; Smith, P.J.; Breytenbach, J.C.; N’Da, D.D.
Synthesis and in vitro antimalarial activity of a series of bisquinoline and bispyrrolo[1,2a]quinoxaline
compounds. Eur. J. Med. Chem. 2012, 55, 335–345. [CrossRef] [PubMed]
37. Vennerstrom, J.L.; Ager, A.L., Jr.; Dorn, A.; Andersen, S.L.; Gerena, L.; Ridley, R.G.; Milhous, W.K.
Bisquinolines. 2. Antimalarial N,N-bis(7-chloroquinolin-4-yl)heteroalkanediamines. J. Med. Chem. 1998, 41,
4360–4364. [CrossRef]
38. Girault, S.; Grellier, P.; Berecibar, A.; Maes, L.; Lemiere, P.; Mouray, E.; Davioud-Charvet, E.; Sergheraert, C.
Antiplasmodial activity and cytotoxicity of bis-, tris-, and tetraquinolines with linear or cyclic amino linkers.
J. Med. Chem. 2001, 44, 1658–1665. [CrossRef] [PubMed]

Molecules 2020, 25, 2251
13 of 15
39. Girault, S.; Grellier, P.; Berecibar, A.; Maes, L.; Mouray, E.; Lemiere, P.; Debreu, M.A.; Davioud-Charvet, E.;
Sergheraert, C. Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-
6-chloro-2-methoxyacridines): Influence of the linker. J. Med. Chem. 2000, 43, 2646–2654. [CrossRef] [PubMed]
40. Ryckebusch, A.; Deprez-Poulain, R.; Maes, L.; Debreu-Fontaine, M.A.; Mouray, E.; Grellier, P.; Sergheraert, C.
Synthesis and in vitro and in vivo antimalarial activity of N1-(7-chloro-4-quinolyl)-1,4-bis(3-aminopropyl)
piperazine derivatives. J. Med. Chem. 2003, 46, 542–557. [CrossRef] [PubMed]
41. Dorn, A.; Vippagunta, S.R.; Matile, H.; Bubendorf, A.; Vennerstrom, J.L.; Ridley, R.G. A Comparison and
Analysis of Several Ways to Promote Haematin (Haem) Polymerisation and an Assessment of Its Initiation
In Vitro. Biochem. Pharmacol. 1998, 55, 737–747. [CrossRef]
42. Dorn, A.; Vippagunta, S.R.; Matile, H.; Jaquet, C.; Vennerstrom, J.L.; Ridley, R.G. An Assessment of Drug-
Haematin Binding as a Mechanism for Inhibition of Haematin Polymerisation by Quinoline Antimalarials.
Biochem. Pharmacol. 1998, 55, 727–736. [CrossRef]
43. Karle, J.M.; Bhattacharjee, A.K.; Vennerstrom, J.L. Crystal structure of the potent bisquinoline antimalarial
agent (+/ )-trans-N-1,N-2-bis(7-chloroquinolin-4-yl) cyclohexane-1,2-diamine dimethanesulfonate salt hydrate
−
in relation to its biological properties. J. Chem. Crystallogr. 2002, 32, 133–139. [CrossRef]
44. Ridley, R.G.; Dorn, A.; Vippagunta, S.R.; Vennerstrom, J.L. Haematin (haem) polymerization and its inhibition
by quinoline antimalarials. Ann. Trop. Med. Parasitol. 1997, 91, 559–566. [CrossRef]
45. Brevent. Nouveaux Dérivés de la Quinoléine et Leur Préparation. Belgium Patent BE612207, 2 July 1962.
46. Burgess, S.J.; Kelly, J.X.; Shomloo, S.; Wittlin, S.; Brun, R.; Liebmann, K.; Peyton, D.H. Synthesis, structure-
activity relationship, and mode-of-action studies of antimalarial reversed chloroquine compounds. J. Med.
Chem. 2010, 53, 6477–6489. [CrossRef]
47. Peyton, D.H. Reversed chloroquine molecules as a strategy to overcome resistance in malaria. Curr. Top.
Med. Chem. 2012, 12, 400–407. [CrossRef] [PubMed]
48. Burgess, S.J. Design and Synthesis of Antimalarial Drugs Based on a Chloroquine Scaffold, Eds; ProQuest Limited
Liability Company, Portland State University: Portland, OR, USA, 2008.
49. Schönhöfer, F. Über die Bedeutung der chinoiden Bindung in Chinolinverbindungen für die Malariawirkung.
Hoppe-Seyler’s Zeitschrift für Physiologische Chemie 1942, 274, 1–8. [CrossRef]
50. Wiselogle, F.Y. A Survey of Antimalarial Drugs, 1941–1945; J. W. Edwards: Ann Arbor, MI, USA, 1946; p. 2500.
51. Andersag, H. Antimalariamittel aus der Gruppe halogensubstituierter Chinolinverbindungen. Chem. Ber.
1948, 81, 499–507. [CrossRef]
52. Coatney, G.R.; Cooper, W.C.; Eddy, N.B.; Greenberg, J. Surveyof antimalarial agents: ChemotherapyofPlasmodium
gallinaceum infections; toxicity; correlation of structure and action. Public Health Monogr. 1953, 9, 1–322.
53. Mietzsch, F. Trends of progress in chemotherapy. Klin. Wochenschr. 1951, 29, 125–135. [CrossRef]
54. Dann, O.; Steuding, W.; Lisson, K.G.; Seidel, H.R.; Fink, E.; Nickel, P. Antimalarial 6-aminoquinolines XV. 6- and
4-aminoquinolines with a tertiary basic alkylated amino group. Gegen Malaria wirksame 6-Aminochinoline.
Arzneimittel-Forsch. 1982, 32, 1219–1223.
55. Egan, T.J.; Hunter, R.; Kaschula, C.H.; Marques, H.M.; Misplon, A.; Walden, J. Structure-function relationships
in aminoquinolines: Effect of amino and chloro groups on quinoline-hematin complex formation, inhibition
of beta-hematin formation, and antiplasmodial activity. J. Med. Chem. 2000, 43, 283–291. [CrossRef]
56. Pisciotta, J.M.; Coppens, I.; Tripathi, A.K.; Scholl, P.F.; Shuman, J.; Bajad, S.; Shulaev, V.; Sullivan, D.J., Jr.
The role of neutral lipid nanospheres in Plasmodium falciparum haem crystallization. Biochem. J. 2007, 402,
197–204. [CrossRef]
57. Egan, T.J. Haemozoin formation. Mol. Biochem. Parasitol. 2008, 157, 127–136. [CrossRef]
58. Ambele, M.A.; Sewell, B.T.; Cummings, F.R.; Smith, P.J.; Egan, T.J. Synthetic Hemozoin (beta-Hematin)
Crystals Nucleate at the Surface of Neutral Lipid Droplets that Control Their Sizes. Cryst. Growth. Des. 2013
,
13, 4442–4452. [CrossRef]
59. Andrews, S.; Burgess, S.J.; Skaalrud, D.; Kelly, J.X.; Peyton, D.H. Reversal agent and linker variants of
reversed chloroquines: Activities against Plasmodium falciparum. J. Med. Chem. 2010, 53, 916–919. [CrossRef]
[PubMed]
60. Madrid, P.B.; Sherrill, J.; Liou, A.P.; Weisman, J.L.; Derisi, J.L.; Guy, R.K. Synthesis of ring-substituted
4-aminoquinolines and evaluation of their antimalarial activities. Bioorg. Med. Chem. Lett. 2005, 15, 1015–1018.
[CrossRef] [PubMed]

Molecules 2020, 25, 2251
14 of 15
61. Barlin, G.B.; Nguyen, T.M.T.; Kotecka, B.; Rieckmann, K.H. Potential Antimalarials. XVII. Di- and Mono-
Mannich Bases of 2(and 4)-[2(and 8)-Trifluoromethylquinolin-4-ylamino]phenol. Aust. J. Chem. 1993, 46,
21–29. [CrossRef]
62. Barlin, G.B.; Tan, W.L. Potential Antimalarials. V. 4-(70-Trifluoromethylquinolin-40-Ylamino)Phenols, 4-[20,70 and
2’,80-Bis(Trifluoromethyl)Quinolin-40-Ylamino]Phenols and N4-Substituted 2,7-(and 2,8-)Bis(Trifluoromethyl)-
Quinolin-4-Amines. Aust. J. Chem. 1985, 38, 1827–1835. [CrossRef]
63. Fielding, A.J.; Lukinovic, V.; Evans, P.G.; Alizadeh-Shekalgourabi, S.; Bisby, R.H.; Drew, M.G.B.; Male, V.;
Del Casino, A.; Dunn, J.F.; Randle, L.E.; et al. Modulation of Antimalarial Activity at a Putative Bisquinoline
Receptor In Vivo Using Fluorinated Bisquinolines. Chemistry 2017, 23, 6811–6828. [CrossRef]
64. Gemma, S.; Campiani, G.; Butini, S.; Joshi, B.P.; Kukreja, G.; Coccone, S.S.; Bernetti, M.; Persico, M.; Nacci, V.;
Fiorini, I.; et al. Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative
and potent hybrid antimalarials. J. Med. Chem. 2009, 52, 502–513. [CrossRef]
65. Kgokong, J.L.; Matsabisa, G.M.; Smithand, P.P.; Breytenbach, J.C. N,N-Bis(trifluoromethylquinolin-
4-yl)diamino alkanes: Synthesis and antimalarial activity. Med. Chem. 2008, 4, 438–445. [CrossRef]
66. Vippagunta, S.R.; Dorn, A.; Matile, H.; Bhattacharjee, A.K.; Karle, J.M.; Ellis, W.Y.; Ridley, R.G.; Vennerstrom, J.L.
Structural specificity of chloroquine-hematin binding related to inhibition of hematin polymerization and
parasite growth. J. Med. Chem. 1999, 42, 4630–4639. [CrossRef]
67. Blackie, M.A.; Beagley, P.; Croft, S.L.; Kendrick, H.; Moss, J.R.; Chibale, K. Metallocene-based antimalarials:
An exploration into the influence of the ferrocenyl moiety on in vitro antimalarial activity in chloroquine-
sensitive and chloroquine-resistant strains of Plasmodium falciparum. Bioorg. Med. Chem. 2007, 15, 6510–6516.
[CrossRef]
68. De, D.; Krogstad, F.M.; Cogswell, F.B.; Krogstad, D.J. Aminoquinolines that circumvent resistance in
Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 1996, 55, 579–583. [CrossRef]
69. Kaschula, C.H.; Egan, T.J.; Hunter, R.; Basilico, N.; Parapini, S.; Taramelli, D.; Pasini, E.; Monti, D. Structure-
activity relationships in 4-aminoquinoline antiplasmodials. The role of the group at the 7-position. J. Med.
Chem. 2002, 45, 3531–3539. [CrossRef] [PubMed]
70. Perez, B.C.; Teixeira, C.; Albuquerque, I.S.; Gut, J.; Rosenthal, P.J.; Gomes, J.R.; Prudencio, M.; Gomes, P.
N-cinnamoylated chloroquine analogues as dual-stage antimalarial leads. J. Med. Chem. 2013, 56, 556–567.
[CrossRef] [PubMed]
71. Pesic, D.; Starcevic, K.; Toplak, A.; Herreros, E.; Vidal, J.; Almela, M.J.; Jelic, D.; Alihodzic, S.; Spaventi, R.;
Peric, M. Design, synthesis, and in vitro activity of novel 2’-O-substituted 15-membered azalides. J. Med.
Chem. 2012, 55, 3216–3227. [CrossRef] [PubMed]
72. Terzic, N.; Konstantinovic, J.; Tot, M.; Burojevic, J.; Djurkovic-Djakovic, O.; Srbljanovic, J.; Stajner, T.;
Verbic, T.; Zlatovic, M.; Machado, M.; et al. Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines
and Tetraoxanes Potential Two-Stage Antimalarials? J. Med. Chem. 2016, 59, 264–281. [CrossRef]
73. Warhurst, D.C.; Gould, S. The chemotherapy of rodent malaria XXXIII. The activity of chloroquine and
related blood schizontocides and of some analogues in drug-induced pigment clumping. Ann. Trop. Med.
Parasitol. 1982, 76, 257–264. [CrossRef]
74. De, D.; Krogstad, F.M.; Byers, L.D.; Krogstad, D.J. Structure-activity relationships for antiplasmodial activity
among 7-substituted 4-aminoquinolines. J. Med. Chem. 1998, 41, 4918–4926. [CrossRef]
75. Claisen, L. Untersuchungen über die Oxymethylenverbindungen. (Zweite Abhandlung.). Justus Liebig’s
Annalen der Chemie 1897, 297, 1–98. [CrossRef]
76. Price, C.C.; Roberts, R.M. The synthesis of 4-hydroxyquinolines; through ethoxymethylene malonic ester.
J. Am. Chem. Soc. 1946, 68, 1204–1208. [CrossRef]
77. Gould, R.G.; Jacobs, W.A. The Synthesis of Certain Substituted Quinolines and 5,6-Benzoquinolines. J. Am.
Chem. Soc. 1939, 61, 2890–2895. [CrossRef]
78. Abel, M.D.; Luu, H.T.; Micetich, R.G.; Nguyen, D.Q.; Oreski, A.B.; Tempest, M.L.; Daneshtalab, M. Synthesis
of azolylalkylquinolines with cytotoxic activity. J. Heterocyclic. Chem. 1996, 33, 415–420. [CrossRef]
79. Ghosh, B.; Antonio, T.; Zhen, J.; Kharkar, P.; Reith, M.E.; Dutta, A.K. Development of (S)-N6-(2-(4-(isoquinolin-
1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydro benzo[d]-thiazole-2,6-diamine and its analogue as a
D3 receptor preferring agonist: Potent in vivo activity in Parkinson’s disease animal models. J. Med. Chem.
2010, 53, 1023–1037. [CrossRef] [PubMed]

Molecules 2020, 25, 2251
15 of 15
80. Surrey, A.R.; Cutler, R.A. The Role of Phenol in the Reaction of 4,7-Dichloroquinoline with Novol Diamine.
J. Am. Chem. Soc. 1951, 73, 2623–2626. [CrossRef]
81. Iwasaki, N.; Sakaguchi, J.; Ohashi, T.; Takahara, E.; Ogawa, N.; Yasuda, S.; Koshinaka, E.; Kato, H.; Ito, Y.;
Sawanishi, H. Amphoteric drugs. I. Synthesis and antiallergic activity of [4-(diphenylmethoxy)piperidino]-,
[4-(diphenylmethyl)piperazinyl]- and [4-(diphenylmethylene)piperidino]alkanoic acid derivatives. Chem. Pharm.
Bull. (Tokyo) 1994, 42, 2276–2284. [CrossRef] [PubMed]
82. Burgess, S.J.; Selzer, A.; Kelly, J.X.; Smilkstein, M.J.; Riscoe, M.K.; Peyton, D.H. A chloroquine-like molecule
designed to reverse resistance in Plasmodium falciparum. J. Med. Chem. 2006, 49, 5623–5625. [CrossRef]
[PubMed]
83. Smilkstein, M.; Sriwilaijaroen, N.; Kelly, J.X.; Wilairat, P.; Riscoe, M. Simple and inexpensive fluorescence-
based technique for high-throughput antimalarial drug screening. Antimicrob. Agents Chemother. 2004, 48,
1803–1806. [CrossRef] [PubMed]
Sample Availability: Not available.
©
2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).